Aspire Biopharma Holdings (ASBP) Receivables - Other (2024)
Aspire Biopharma Holdings' (ASBP) quarterly Receivables - Other came in at $36503.0 in Q4 2024, up 45.81% quarter-over-quarter from $25034.0 in Q3 2024.
Powered by 
Analysis
Aspire Biopharma Holdings (ASBP) Receivables - Other (2024) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Receivables - Other for 1 consecutive years, with $36503.0 the latest figure, recorded in Q4 2024.
- On a quarterly basis, Receivables - Other changed N/A year-over-year to $36503.0 in Q4 2024; TTM through Dec 2024 was $36503.0, a N/A change from a year earlier, with the FY2024 full-year figure at $36503.0, changed N/A from the prior year.
- Receivables - Other was $36503.0 for Q4 2024 at Aspire Biopharma Holdings, up from $25034.0 in the prior quarter.
- Over five years, Receivables - Other peaked at $299921.0 in Q2 2024 and troughed at $25034.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Aspire Biopharma Holdings | 64.13 Mn | 51.96 Mn | -30,086.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 36,503.00 |
| Sep 30, 2024 | 25,034.00 |
| Jun 30, 2024 | 299,921.00 |